Dr. Sophie Dupuis-Girod holds an M.D. from René Descartes University, Paris V, with specializations in pediatrics and clinical genetics, and a Ph.D. in clinical research from the University of Lyon. She has been at the helm of the French HHT National Reference Center since 2005, assuming its coordination in 2012. Internationally, she has served as co-chair and, since 2021, as chair of the HHT group within the VASCERN network.
Her active involvement in the clinical management of HHT patients dates back to 2005, and she has been instrumental in advancing clinical research and developing new treatments since 2009. Notably, Dr. Sophie Dupuis-Girod led the pioneering therapeutic trial of anti-angiogenic treatments for HHT and has since directed seven therapeutic trials as the principal investigator.